429 related articles for article (PubMed ID: 10713666)
1. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
Bullock AN; Henckel J; Fersht AR
Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
Selivanova G; Wiman KG
Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.
Rippin TM; Bykov VJ; Freund SM; Selivanova G; Wiman KG; Fersht AR
Oncogene; 2002 Mar; 21(14):2119-29. PubMed ID: 11948395
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A; Rotter V
Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
[TBL] [Abstract][Full Text] [Related]
6. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.
Lubin DJ; Butler JS; Loh SN
J Mol Biol; 2010 Jan; 395(4):705-16. PubMed ID: 19913028
[TBL] [Abstract][Full Text] [Related]
7. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
8. Folding and misfolding mechanisms of the p53 DNA binding domain at physiological temperature.
Butler JS; Loh SN
Protein Sci; 2006 Nov; 15(11):2457-65. PubMed ID: 17001034
[TBL] [Abstract][Full Text] [Related]
9. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
[TBL] [Abstract][Full Text] [Related]
10. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
11. [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
Müller P; Nenutil R; Vojtĕsek B
Cas Lek Cesk; 2004; 143(5):313-7. PubMed ID: 15305766
[TBL] [Abstract][Full Text] [Related]
12. Structure and functionality of a designed p53 dimer.
Davison TS; Nie X; Ma W; Lin Y; Kay C; Benchimol S; Arrowsmith CH
J Mol Biol; 2001 Mar; 307(2):605-17. PubMed ID: 11254385
[TBL] [Abstract][Full Text] [Related]
13. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants.
Friedler A; Hansson LO; Veprintsev DB; Freund SM; Rippin TM; Nikolova PV; Proctor MR; Rüdiger S; Fersht AR
Proc Natl Acad Sci U S A; 2002 Jan; 99(2):937-42. PubMed ID: 11782540
[TBL] [Abstract][Full Text] [Related]
14. Kinetic partitioning during folding of the p53 DNA binding domain.
Butler JS; Loh SN
J Mol Biol; 2005 Jul; 350(5):906-18. PubMed ID: 15982667
[TBL] [Abstract][Full Text] [Related]
15. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
[TBL] [Abstract][Full Text] [Related]
16. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
17. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein.
Vojtesek B; Dolezalova H; Lauerova L; Svitakova M; Havlis P; Kovarik J; Midgley CA; Lane DP
Oncogene; 1995 Jan; 10(2):389-93. PubMed ID: 7530828
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
[TBL] [Abstract][Full Text] [Related]
19. Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations.
Mathe E; Olivier M; Kato S; Ishioka C; Vaisman I; Hainaut P
Hum Mutat; 2006 Feb; 27(2):163-72. PubMed ID: 16395672
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
